Cancers, Vol. 12, Pages 988: Challenges for Immunotherapy in Multiple Myeloma: Bone Marrow Microenvironment-Mediated Immune Suppression and Immune Resistance
Cancers, Vol. 12, Pages 988: Challenges for Immunotherapy in Multiple Myeloma: Bone Marrow Microenvironment-Mediated Immune Suppression and Immune Resistance
Cancers doi: 10.3390/cancers12040988
Authors:
Lisa C. Holthof
Tuna Mutis
The power of immunotherapy in the battle of Multiple Myeloma (MM) started with allogeneic stem cell transplantation, and was rediscovered with immunomodulatory drugs and extended with the outstanding results achieved with targeted antibodies. Today, next to powerful antibodies Elotuzumab and Daratumumab, several T-cell-based immunotherapeutic approaches, such as bispecific antibodies and chimeric antigen receptor-transduced T-cells (CAR T-cells) are making their successful entry in the immunotherapy arena with highly promising results in clinical trials. Nonetheless, similar to what is observed in chemotherapy, MM appears capable to escape from immunotherapy, especially through tight interactions with the cells of the bone marrow microenvironment (BM-ME). This review will outline our current understanding on how BM-ME protects MM-cells from immunotherapy through immunosuppression and through induction of intrinsic resistance against cytotoxic effector mechanisms of T- and NK-cells.
Source: Cancers - Category: Cancer & Oncology Authors: Lisa C. Holthof Tuna Mutis Tags: Review Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Clinical Trials | Immunotherapy | Myeloma | Stem Cell Therapy | Stem Cells | Transplants